Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 19/20 | 0.51 |
| ▸ | FLT3 | P36888 | 11/20 | 0.50 |
| ▸ | JAK2 | O60674 | 9/20 | 0.50 |
| ▸ | SRC | P12931 | 5/20 | 0.50 |
| ▸ | ZAP70 | P43403 | 5/20 | 0.50 |
| ▸ | LYN | P07948 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 3/20 | 0.49 |
| ▸ | ALPL | P05186 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25330999 | 0.85 | SYK (0.48) | SYKFLT3JAK2SRCZAP70 | |
| Hydrochloric Acid SCHEMBL25329360 | 0.78 | SYK (0.70) | SYKFLT3JAK2ZAP70LYN | |
| Hydrochloric Acid SCHEMBL31074721 | 0.78 | SYK (0.70) | SYKFLT3JAK2ZAP70LYN | |
| SCHEMBL25329089 | 0.78 | SYK (0.72) | SYKFLT3JAK2LYN | |
| SCHEMBL29492115 | 0.76 | SYK (0.72) | SYKFLT3JAK2ZAP70LYN | |
| SCHEMBL25328291 | 0.76 | SYK (0.72) | SYKFLT3JAK2ZAP70LYN | |
| SCHEMBL25328300 | 0.76 | SYK (0.72) | SYKFLT3JAK2ZAP70LYN | |
| SCHEMBL25330180 | 0.75 | SYK (0.60) | SYKFLT3JAK2LYN | |
| SCHEMBL14216071 | 0.73 | SYK (0.70) | SYKFLT3JAK2SRCZAP70 | |
| SCHEMBL14216141 | 0.73 | SYK (0.70) | SYKFLT3JAK2SRCZAP70 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240285621-A1 | PYRAZOLYL-PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2024-08-29 | — | — | US | disclosed |
| EP-4217354-A1 | PYRAZOLYL-PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2023-08-02 | — | — | EP | disclosed |
| CN-116323595-A | Pyrazolyl-pyrimidine derivatives as kinase inhibitors | 内尔维亚诺医疗科学公司 | 2023-06-23 | — | — | CN | disclosed |
| WO-2022063646-A1 | PYRAZOLYL-PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240285621-A1 | PYRAZOLYL-PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | SYK, LCK, BTK | SYK 1/4885FLT3 28/4885JAK2 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.